Novi vs MEDVi vs TrimRx: Which Telehealth GLP-1 Wins for 2026

By HollyHerman.com Wellness Team | Updated May 2026

This article is for informational purposes only and is not medical advice. All pricing referenced is based on each platform's publicly available materials as of the date of publication and is subject to change. Compounded medications referenced are not FDA-approved for safety, effectiveness, or quality. Always consult a licensed healthcare provider before starting any prescription weight loss medication.

By the time most women land on this comparison, they've already done the work. They've decided that GLP-1 therapy is potentially appropriate for their situation. They've ruled out brand-name retail because the cost without insurance is unsustainable. They've looked at one or two telehealth platforms and now they want to compare. The question is no longer “should I do this?” — it's “which platform makes the most sense for me?”

I've reviewed Novi, MEDVi, and TrimRx in depth on this site. Each has distinct positioning, distinct strengths, and distinct trade-offs. None of them is universally “the best.” The right answer depends on your specific situation: budget, risk tolerance, medication preference, and how much support you need during the first three months. Here's the honest comparison.

The Quick Summary

If pricing is your primary decision factor, Novi is the cheapest published starting price on compounded semaglutide. If clinical-educational depth is your priority, MEDVi leans most heavily into the medical-evaluation model. If pricing transparency and a no-surprises feel are your priorities, TrimRx is the platform that puts the all-in numbers most clearly on the front page.

All three platforms operate with U.S.-licensed clinicians, U.S.-licensed compounding pharmacies, and standard HIPAA-compliant privacy practices. All three offer compounded semaglutide and compounded tirzepatide. None of them is FDA-approved as a compounded formulation — that's a category-wide regulatory distinction, not a platform-specific concern. The choice between them is about pricing, support model, and personal fit.

Pricing Comparison

Here are the published starting prices as of the date of publication. All pricing is subject to change; confirm current prices on each platform's official site before signing up.

Novi compounded semaglutide: Starts at $174 per month, with a 3-month minimum commitment per the Terms of Service. First-3-months total: $522.

Novi compounded tirzepatide: Starts at $283 per month, with the same 3-month minimum commitment. First-3-months total: $849.

MEDVi GLP-1 program: Pricing varies by program tier and consultation type. The platform leans toward an educational-clinical model with the medication priced as part of a broader program rather than a flat-monthly. Read my full MEDVi review for the current program structure.

TrimRx compounded semaglutide: Starts at $199 per month for injectables. No minimum commitment specified in publicly available materials at the same level of clarity as Novi's 3-month commitment.

TrimRx compounded tirzepatide: Starts at $349 per month. See my TrimRx review for full details on payment options including HSA/FSA acceptance and Afterpay/Klarna/Affirm.

On a straight monthly comparison, Novi is meaningfully cheaper than TrimRx on both semaglutide ($174 vs $199, a $25 difference) and tirzepatide ($283 vs $349, a $66 difference). The catch with Novi is the 3-month commitment built into the Terms of Service. TrimRx has more flexibility on month-to-month exit. For the full Novi math see my Novi cost breakdown.

The Commitment Question

Of the three platforms, Novi is the most explicit about the 3-month commitment. The Terms of Service plainly state that subscription services require a minimum 3 consecutive months and that the first month plus the next two months is charged at the time of purchase and is non-refundable except in the case of medical-eligibility denial. The company also notes it will defend chargeback disputes from customers attempting to circumvent the commitment.

I respect the directness of that disclosure. It's clearer than telehealth platforms that bury similar terms in dense legalese. The trade-off is that you genuinely cannot test Novi for one month and back out. Your day-one decision is committing $522 to $849 depending on which medication.

TrimRx's commitment structure as published is more flexible — closer to month-to-month with the ability to cancel between cycles. This is a meaningful difference if your situation is uncertain (you're not sure GLP-1 is right for you, your insurance status may change, your job situation is in flux). The flexibility comes at a slightly higher monthly price.

MEDVi's structure varies by program. Read the program-specific Terms before enrolling.

Provider Models Compared

All three platforms use a combination of physicians (MD/DO) and nurse practitioners (NP/DNP) for clinical evaluation and prescription oversight. Novi publishes a named provider directory including Daniel Funsch MD (Emergency Medicine board-certified), Kimberli Hastings NP, Kristine Clements NP (25+ years experience including USAF flight medic), Michael Wasef MD (Internal Medicine), Theresa Vergara NP DNP, and Takashi Nakamura MD (Emergency Medicine).

That's a reasonable mix of specialties for telehealth weight management. The presence of Internal Medicine board-certification specifically is positive — internal medicine specialists tend to be the most comfortable managing the metabolic and cardiovascular comorbidities that often accompany the patient population appropriate for GLP-1 therapy.

Provider rotation is standard across all three platforms. Which specific clinician you see depends on your state of residence and scheduling availability. The named directory is the platform's roster — it's not a guarantee of which provider will see you.

Support Models

All three platforms advertise unlimited clinician access, ongoing dose-adjustment support, and 24/7 messaging through a patient portal. The practical differences come down to provider response time, the structure of coaching support, and the depth of educational content provided to patients during treatment.

Novi includes coaching at no additional cost as part of the standard monthly subscription. The coaching structure was not detailed extensively in the public materials I reviewed — confirm the format and frequency at signup if coaching matters to your decision.

MEDVi tends to lean more heavily on the clinical-educational model. The platform positions itself closer to a medical service than a convenience service.

TrimRx publishes 100,000+ customers served with a 4.8 reported rating, which suggests volume operations and the systems to support it. Customer reviews specifically mention thorough provider consultations and proactive dose adjustment outreach as positives.

Pharmacy Sourcing and Quality

All three platforms use U.S.-licensed compounding pharmacies operating under state pharmacy board oversight. None of the three publishes the specific names of partner pharmacies in marketing materials, which is consistent across the compounded telehealth industry — pharmacy partnerships are typically business-confidential.

TrimRx specifically mentions LegitScript certification of its pharmacy partners, which is an independent third-party verification standard for legitimate pharmacy operations. This is a meaningful disclosure and one I'd want to see on more platforms in this space.

The compounded medication itself is the same active pharmaceutical ingredient regardless of platform. The differences are in pharmacy quality systems, batch consistency, and the specific compounding processes — none of which are fully visible to patients before signing up. The available trust signals are licensure, certifications, and operational track record.

What Each Platform Does Best

Each of these three platforms has a clearest-best-fit reader profile based on what the platform optimizes for.

Novi is best for: the woman who has decided to commit to a full 3-month protocol, wants the lowest published starting price on compounded semaglutide, values the all-inclusive monthly fee structure (no separate consultation, refill, or membership fees), and is comfortable with the 3-month commitment being the day-one financial decision. The women-forward marketing and testimonials suggest the platform is built specifically for this demographic.

MEDVi is best for: the patient who wants more clinical-educational depth in the experience, is comfortable with a slightly more medical-feeling enrollment process, and values the ongoing clinical support model. MEDVi's positioning sits closer to a medical service than a convenience service. Read my full MEDVi review for the detailed walk-through.

TrimRx is best for: the patient who wants pricing transparency, no commitment trap, the flexibility of month-to-month cancellation, and the option of HSA/FSA payment plus financing through Afterpay/Klarna/Affirm if needed. The slightly higher monthly price compared to Novi is the cost of the commitment flexibility. See my TrimRx review for the full breakdown.

What None of Them Does Particularly Well

An honest comparison includes the limitations all three platforms share. None of the three is fully transparent on the homepage about the compounded-versus-FDA-approved distinction. All three lean into “same active ingredient as Ozempic” or similar framing without front-loading the regulatory clarification. That's a category-wide criticism — it applies across compounded telehealth GLP-1 in general — but it deserves to be named.

None of the three publishes batch testing results, certificate of analysis information, or detailed pharmacy operational data publicly. This is consistent with how compounded medication businesses operate, but it does mean patients are relying on regulatory framework rather than direct quality verification.

None of the three appears to offer a clear pre-treatment lab work integration in the standard patient flow. Most clinical guidelines for GLP-1 therapy recommend baseline metabolic panel, lipid panel, and HbA1c testing before starting and at intervals during treatment. Patients on these platforms often need to coordinate lab work separately through their primary care provider or direct-to-consumer lab services. Budget accordingly.

The Comparison Math at the 3-Month Mark

For an apples-to-apples 3-month total comparison on compounded semaglutide:

Novi: $174 × 3 = $522 (locked-in commitment, non-refundable except for medical-eligibility denial)

TrimRx: $199 × 3 = $597 (with the option to cancel between months if needed)

The Novi savings versus TrimRx on a full 3-month run is $75. The trade-off is that Novi's $522 is committed up front and locked in by the Terms of Service; TrimRx's $597 builds month-by-month and can be exited if your situation changes. For some patients the Novi savings is worth the commitment trade-off. For others, the TrimRx flexibility is worth $75.

For tirzepatide:

Novi: $283 × 3 = $849 (committed)

TrimRx: $349 × 3 = $1,047 (flexible)

The savings differential on tirzepatide is more meaningful — $198 over three months. Same trade-off in structure.

Other Telehealth GLP-1 Platforms Worth Knowing About

Beyond these three, the compounded GLP-1 telehealth space includes platforms like AgelessRx (which positions itself in the longevity-optimization space and offers GLP-1 microdosing alongside a much broader catalog of off-label longevity protocols), Hims/Hers and Ro (general telehealth with GLP-1 as one offering among many), and a number of newer entrants.

For the longevity-positioning angle specifically, see my AgelessRx review. For the broader weight loss category including alternatives outside the prescription GLP-1 space, browse the weight loss category.

Considerations Beyond the Platform Choice

Whichever platform you choose, the lifestyle scaffolding around GLP-1 treatment matters more than the platform decision itself. Adequate protein (1.2 to 1.6 grams per kilogram of body weight). Resistance training to protect lean muscle mass during weight loss. Hydration management as food intake drops. Fiber adequacy for managing constipation. Sleep prioritization. Lab work to track metabolic markers. None of this is platform-specific. All of it determines whether your GLP-1 protocol produces durable results or just temporary scale-weight loss.

For more on the underlying medication and how it works, see my how compounded GLP-1 works piece. For the realistic side effect picture during the first month, see GLP-1 side effects in women. For the full Novi review covering everything from the provider directory to the refund policy, see the main Novi review.

The Bottom Line on the Comparison

If forced to pick a single winner from the three: it depends on what the reader is optimizing for. Novi wins on lowest-published starting price and women-forward marketing fit.TrimRx wins on commitment flexibility and pricing transparency.MEDVi wins on clinical-educational depth.

The reader who is committed to a full 3-month protocol, has no insurance route to brand-name medication, and has the budget for the up-front commitment will likely come out ahead with Novi. The reader who needs the option to test for one month before fully committing will likely be better served by TrimRx. The reader who wants the most medical-feeling experience may prefer MEDVi.

None of these platforms is a wrong choice for their target reader. All three are operating within compliant compounded GLP-1 telehealth practice, and all three have distinct positioning that suits different patient needs. The wrong choice is signing up for a platform whose commitment structure doesn't match your situation, or signing up without understanding the compounded-versus-FDA-approved distinction in the medication you're injecting.

Read the Terms of Service before you sign up — on whichever platform you choose. Confirm pricing on the official site. Plan for the supporting nutrition and lifestyle structure. And give the protocol a fair three months before drawing conclusions about whether it works for your body.

Editorial note: All pricing referenced in this article is based on each platform's publicly available materials as of the date of publication. Pricing and Terms of Service are subject to change without notice. Compounded semaglutide and compounded tirzepatide are not FDA-approved for safety, effectiveness, or quality. This article is for informational purposes only and does not constitute medical advice or financial advice.